Sankara Nethralaya Signs MOU for Retinoblastoma management during Retinoblastoma Awareness Week.

Sankara Nethralaya and Sri Ramachandra Institute of Higher Education and Research (SRIHER) signed a Memorandum of Understanding (MoU) on Friday, 19th May 2023 for collaborative initiatives in the management of Retinoblastoma (childhood eye cancer).  The MoU signing ceremony coincided with the Retinoblastoma Awareness program held on May 15th, 2023 to observe World Retinoblastoma Week from 14th May – 20th May 2023.  

Dr. Girish S. Rao, President (MRF) and Dr Sudagar Singh, MD, SRIHER, signed this historic MoU, which will pave the way for the joint management of Retinoblastoma by a multidisciplinary team, including ocular brachetherapy, facilitation of multidisciplinary team meetings and the sharing of medical expertise, such as a medical physicist, etc.  With this collaboration, ocular oncologists from Sankara Nethralaya will be able to work routinely with radiologists, radiation oncologists and pediatric oncologists from SRIHER in a concentrated effort to save more human lives, preserve vision and globe salvage.

Present at the signing of the MoU were Dr. K. Balaji Singh, Dean, Dr Uma Shekar, Vice Chancellor, Dr. Mahesh Vakamudi Pro Chancellor, Dr. K. V. Somasundaram, Academic Officer, Dr. Sudhagar Singh, Medical Director, Dr. Radha Annamalai HOD – Ophthalmology, Dr. Julius Scott, HOD – Pediatric Oncology, and Dr. Satish Srinivas, HOD – Radiation Oncology from SRIHER.

Dr. T. S. Surendran, Chairman & Director – Pediatric Ophthalmology, Dr. Pramod Bhende, Director, Shri Bhagwan Mahavir Department of Vitreo Retinal Services and Dr. Suganeswari Ganesan, Senior consultant, (Vitreoretina and Ocular Oncologist) represented Sankara Nethralaya’s Retinoblastoma team of doctors on this occasion.

Raising Awareness during World Retinoblastoma Week

World Retinoblastoma Awareness Week was observed by the Retinoblastoma team at Sankara Nethralaya between May 8th and May 14th 2022. From arranging a press meet to setting up a white board at the entrance to the MAHYCO block for the young retinoblastoma survivors to place their hand – stamps. The Retinoblastoma team poured their hearts and souls into highlighting this curable childhood cancer, its prevention, and cure, and to spread awareness about this disease to the general public. Over 150 children with childhood eye cancers are treated by Sankara Nethralaya each year – one of the highest treatment rates in the world. This institution is also one of the few eye care facilities in India to specialise in childhood eye cancer (Retinoblastoma). Sankara Nethralaya offers cost-free treatment to the children from disadvantaged backgrounds and does not discriminate on the treatment.

Dr Charanya C, Associate Consultant, Viteoretinal services gave a short introduction, titled “Retinoblastoma – an eye opener,” focusing on the fact that fighting Retinoblastoma in children is a team effort. She explained that familial or heredity contributed to several cases, in which instance, the disease can even be prevented in the womb.

The press meet included a panel of doctors who are involved in treating children with childhood eye cancer, alongside Sankara Nethralaya’s well-experienced retinoblastoma specialists to field the questions from the press. The panel included Dr Veena Noronha, Senior Radiologist; V. R. R Scans; Dr. K. Satish Srinivas and Dr. Christopher John, Radiation Oncology, Ramachandra Medical Centre, Dr Pritam Chatterjee, and Dr. (Prof) S. Krishna Kumar, Chief Scientist, Laboratory Services – Histo Pathology Lab, among others. Dr. Lingam Gopal, Distinguished Senior Consultant and Dr. G. Suganeswari, Senior Consultant, Department of Vitreo Retinal Services were present to moderate and field questions from the press.

The panel of doctors stressed the fact that this disease was not just managed by a single ocular oncologist but many people such as a paediatrician, paediatric oncologist, an anaesthetist, a radiologist, an intervention radiologist. The priority for the Retinoblastoma team at Sankara Nethralaya is to first try and save the life of the children, the second priority is to save the eye and thirdly, save the vision, if possible.

Dr. G. Suganeswari, Senior Consultant, Vitreoretina and Oncology Services, said, “Retinoblastoma is a curable childhood cancer and it is a very common cancer in the childhood period. In India, every year, 2000 children are born with the disease, which means one in eighteen thousand children are born with a retinoblastoma and these children belong to the lower social economic strata.”

The parents find it difficult to afford the expensive and prolonged treatment. The Retinoblastoma team helps these children with the most advanced treatment for different stages of retinoblastoma, from intraocular tumours, to tumours which have already spread away from the eye (extraocular tumours), and tumours which have already spread to the organs- distant metastasis.

A few of the patients and their guardians were also present to tell their stories and contribute towards raising awareness about the disease. Two of the patients had familial retinoblastoma, while the cause of the disease was unknown (sporadic) for one patient. The families of the child survivors were very appreciative of the chance to speak about this disease and how their children were lucky to be treated cost-free as even the middle class families cannot afford the cost of lengthy treatments.

Dr. G. Suganeswari reiterated that the patients she had treated were all bright and had great futures – with the support of their families these cancer survivors could go on to achieve greater things. She also cautioned everyone present that the survivors of childhood eye cancer had to come back for regular follow-ups as they had a chance of developing other cancers later in life.

Sankara Nethralaya is one of the few hospitals where the chemotherapy is an in-house facility to make it easier for the patients to get all treatments under one single roof. Housing a chemotherapy ward involves a lot of commitment from many people and requires collaboration with other fraternity hospitals to manage the child patients.

The gathering was reassured that there were many NGOs and charities who are coming forward to help these child patients get cost-free life and vision saving treatment. The press meet closed on a positive note with the doctors assuring everyone that it was possible to save the life of every child, if timely treatment was given.

Concern and Compassion come calling from across the globe

We are all familiar with the dictum ‘Do your best and God will take care of the rest” good acts after all seldom go unnoticed. It was such devoted, sincere and selfless efforts by the members of Sankara Nethralaya Ophthalmic Mission Trust, USA towards raising funds to light up lives in their home country and […]

Continue Reading

Oculoplasty doctors win awards at PARADIGM 2010

Dr. Bipasha Mukherjee, Director, Orbital Diseases & Oculoplasty, Dr. Marian Jacob and Dr. Puja Goyal, Fellows, Orbital Diseases & Oculoplasty, won accolades at the recently held annual Oculoplasty Association of India conference. Titled PARADIGM 2010, the conference, which took place at the Tata Memorial Cancer Hospital, Mumbai from November 19 to November 21, 2010, saw […]

Continue Reading

Annual meeting on ophthalmic research held

Nineteen scientists from the Vision Research Foundation participated at the 18th Indian Eye Research Group (IERG) meeting at Hyderabad held from July 31 to August 1, 2010. Held from 1992, the annual IERG meeting brings together investigators involved in different areas of basic and clinical eye research across India to discuss the latest research methodologies […]

Continue Reading

Sankara Nethralaya at ARVO 2010

The annual ARVO conference, which was held at Fort Lauderdale, Florida, US, saw ophthalmic experts from around the world participate in a series of symposia, poster presentations and deliberations. A seven-member team from Sankara Nethralaya took part at the event held from May 2- May 6. Dr. Lingam Gopal, senior Vitreo Retinal consultant and Director, Research, […]

Continue Reading